Eroxmit 750

Each vial of reconstituted sterile powder for injection contains Cefuroxime sodium equivalent to Cefuroxime 750 mg.

Pharmacology: Pharmacodynamics: Mechanism of Action: Bactericidal; action depends on ability to reach and bind penicillin-binding proteins located in bacterial cytoplasmic membranes. Cephalosporins inhibit bacterial septum and cell wall synthesis, probably by acylation of membrane-bound transpeptidase enzymes. This prevents cross-linkage of peptidoglycan chains, which is necessary for bacterial cell wall strength and rigidity. Also, cell division and growth are inhibited, and elongation of susceptible bacteria and lysis frequently occur. Rapidly dividing bacteria are those most susceptible to the action of cephalosporins.
Pharmacokinetics: Widely distributed throughout the body and reach therapeutic concentrations in most tissues and body fluids, including synovial, pericardial, pleural, and peritoneal fluids, bile; sputum and urine. Also distributed into bone, the gall bladder, the myocardium, and skin and soft tissue. Most cephalosporins cross the placenta and are distributed into breast milk.

Second generation cephalosporins enhanced activity against Escherichia coli, Klebsiella spp., and Proteus mirabilis. In addition, they have greater activity in vitro against a larger number of gram-negative bacteria, including Haemophilus influenzae, indole-positive Proteus, Neiserria meningitidis, N. gonorrheae and some strains of Serratia and Enterobacter spp.
Cefuroxime is the only second-generation cephalosporin to adequately penetrate into the cerebral spinal fluid (CSF).
Cefuroxime is used in the treatment of septicemia, bone and joint infections, gram-negative pneumonia, skin and soft tissue infections, including burn wound infections, and urinary tract infections caused by susceptible bacterial organisms.
Cefuroxime is commonly used to treat community-acquired pneumonias because of its activity against S. pneumoniae, S.aureus and H. influenzae. Also to treat meningitis caused by S. pneumoniae, H. influenzae and N. meningitidis.

Adult and Adolescent: Intramuscular or Intravenous Infusion: 750 mg to 1.5 grams (base) every 8 hours.
Note: Gonococcal Infections (Uncomplicated): Intramuscular: 1.5 grams (base), divided into 2 doses and administered at two separate sites and 1 gram of probenecid orally, administered simultaneously as single dose.
Meningitis, Bacteria: Intravenous: up to 3 grams (base) every eight hours.
Preoperative Prophylaxis in Open Heart Surgical Patients: Intravenous: 1.5 grams (base) ½ to 1 hour prior to the start of the surgery; 750 mg intravenously or intramuscularly every 8 hours if the surgical procedure is prolonged for up to 24 hour.
Pediatric Dose: Neonates: Intramuscular or Intravenous: 10 to 33.3 (base) per kg of body weight every 8 hours; or 15 to 50 mg per kg of body weight every 12 hours.
Infants and Children 3 Months of Age and Over: Intramuscular or Intravenous: 16.7 to 33.3 mg (base) per kg of body weight every 8 hours.
Note: Bone Infections: Intravenous: 50 mg (base) per kg of body weight every 8 hours meningitis.
Bacteria (Neonates): Intravenous: 33.3 mg (base) per kg of body weight 8 hours or 50 mg per kg of body weight every 12 hours.
Pediatric patients with impaired renal function may require a reduction in the frequency of dosage consistent with adult dosage recommendations in renal impairment.
Or as prescribed by the physician.

Should not be used in patients with previous allergic reaction (anaphylaxis) to penicillins, penicillin derivatives, penicillamine or cephalosporins.

Cross-sensitivity: Patients allergic to cephalosporins, cephamycin, penicillins, penicillin-derivatives may be allergic to other cephalosporins.
Mutagenicity: Not shown.
Carcinogenicity/Fertility: Not been done.
Dental: Long term therapy may allow for overgrowth of Candida albicans (oral candidiasis).
Use in Pregnancy: Cross the placenta.
Use in Lactation: Excreted in breast milk, usually in low concentrations.
Use in Children: Lower metabolic and/or renal clearance with resulting prolonged half-life.
Use in Elderly: No problems have been documented. However, elderly patients are more likely to have an age-related decrease in renal function, which may require an adjustment of dosage and/or dosing interval.

Use in Pregnancy: Cross the placenta.
Use in Lactation: Excreted in breast milk, usually in low concentrations.

Signs of potential side effects, especially pseudomembranous colitis, allergic reactions, hypoprothrombinemia, oral candidiasis, seizures, hypersensitivity, gastrointestinal and serum sickness-like reactions, vaginitis, thrombophlebitis, especially pseudomembranous colitis, and the need for medical attention if they occur after medication is discontinued.
Treatment: If hypersensitivity reactions occur, cephalosporin should be discontinued and should be treated with usual (epinephrine or other pressor amines, antihistamines, or adrenocorticoids), oxygen, and airway management, including intubation. If seizures occur, cephalosporin should be discontinued. Anticonvulsants may be administered if clinically indicated.

Store at temperatures not more than 25°C. Protect from light.

Cephalosporins

J01DC02 - cefuroxime ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.

Rx